Idiopathic Pulmonary Fibrosis (IPF) Therapeutics
Antineoplastics
Customized
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics
Idiopathic pulmonary fibrosis (IPF) therapeutics include APIs developed to slow disease progression, reduce fibrotic tissue formation, and improve respiratory function in patients with chronic and progressive lung fibrosis. Key agents include pirfenidone and nintedanib, which inhibit fibrogenic cytokines, growth factor signaling, and pathways involving TGF-β, VEGF, and PDGF. These drugs reduce fibroblast proliferation, collagen deposition, and inflammatory signaling in lung tissue. Although IPF remains incurable, these therapies significantly delay functional decline and increase quality of life. IPF therapeutics are essential for managing symptoms, reducing exacerbations, and extending survival in affected patients. Ongoing research focuses on combination regimens, antifibrotic biologics, and precision-medicine approaches.
Unit Price:Get Price
CAS No.:799264-47-4
Grade:Pharmacy Grade
Content:99.90%
Packaging:Customizable
Unit Price:Get Price
CAS No.:848353-85-5
Grade:Pharmacy Grade
Content:99.90%
Packaging:Customizable
Unit Price:Get Price
CAS No.:894783-71-2
Grade:Pharmacy Grade
Content:99.90%
Packaging:Customizable
Unit Price:Get Price
CAS No.:912570-13-9
Grade:Pharmacy Grade
Content:99.90%
Packaging:Customizable
Unit Price:Get Price
CAS No.:928326-83-4
Grade:Pharmacy Grade
Content:99.90%
Packaging:Customizable
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.